Cellular Therapy Program News Today

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

The University of Kentucky broke ground today on the new UK Cancer and Advanced Ambulatory Building, located across from UK Albert B. Chandler Hospital on South Limestone. The 550,000-square-foot facility will become the new home to the UK Markey Cancer Center, Kentucky's only National Cancer Institute-designated Comprehensive Cancer Center, as well as a Comprehensive Spine Center, ambulatory surgery space, and other outpatient services.  The Cancer and Advanced Ambulatory Building a...

20.02.2024 - Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is ... Seite 1

Omeros Corporation today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros'...

A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.

/PRNewswire/ -- The National Cord Blood Network (NCBN) proudly announces its official launch, signaling a new era of advances and collaboration in cord blood...

In early December, CRISPR-Cas9 gene editing therapy was approved by the Food and Drug Administration for the treatment of sickle cell in patients ages 12 and up. It’s the first FDA approval for the gene-editing therapy, whose creators won the Nobel Prize in chemistry in 2020.

NJ-based Atlantic Health System is the first in the U.S. to enroll a patient in a study to examine the effectiveness of using Chimeric Antigen Receptor (CAR- T)

TriStar Centennial doctor led national CRISPR clinical trial